[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3294273A4 - Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device - Google Patents

Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device Download PDF

Info

Publication number
EP3294273A4
EP3294273A4 EP16793347.2A EP16793347A EP3294273A4 EP 3294273 A4 EP3294273 A4 EP 3294273A4 EP 16793347 A EP16793347 A EP 16793347A EP 3294273 A4 EP3294273 A4 EP 3294273A4
Authority
EP
European Patent Office
Prior art keywords
lumen
intestinal tract
antibody preparations
delivery device
swallowable drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16793347.2A
Other languages
German (de)
French (fr)
Other versions
EP3294273A1 (en
Inventor
Mir Imran
Radhika KORUPOLU
Elaine TO
Mir Hashim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rani Therapeutics LLC
Original Assignee
Incube Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incube Laboratories LLC filed Critical Incube Laboratories LLC
Publication of EP3294273A1 publication Critical patent/EP3294273A1/en
Publication of EP3294273A4 publication Critical patent/EP3294273A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16793347.2A 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device Pending EP3294273A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159134P 2015-05-08 2015-05-08
PCT/US2016/031548 WO2016183040A1 (en) 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Publications (2)

Publication Number Publication Date
EP3294273A1 EP3294273A1 (en) 2018-03-21
EP3294273A4 true EP3294273A4 (en) 2018-12-05

Family

ID=57248408

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16793347.2A Pending EP3294273A4 (en) 2015-05-08 2016-05-09 Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Country Status (6)

Country Link
EP (1) EP3294273A4 (en)
JP (2) JP7185401B2 (en)
CN (1) CN107835682A (en)
AU (2) AU2016261599B2 (en)
CA (1) CA2984422C (en)
WO (1) WO2016183040A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058595B2 (en) 2014-05-15 2018-08-28 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2016320867B2 (en) * 2015-09-08 2023-03-30 Rani Therapeutics, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA3046093A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
WO2020142538A1 (en) * 2018-12-31 2020-07-09 Incube Labs, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031770A2 (en) * 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2009063222A2 (en) * 2007-11-15 2009-05-22 Ucl Business Plc Solid compositions
US20120027775A1 (en) * 2010-08-02 2012-02-02 Advanced Technologies And Regenerative Medicine, Llc Absorbable peg-based hydrogels
WO2014066468A1 (en) * 2012-10-25 2014-05-01 Medimmune, Llc Stable, low viscosity antibody formulation
WO2015176031A2 (en) * 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024767B2 (en) * 1979-08-24 1985-06-14 塩野義製薬株式会社 enteric-coated hard capsules
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
EP3461478B1 (en) 2009-12-24 2020-04-22 Rani Therapeutics, LLC Swallowable drug delivery device
US8721620B2 (en) * 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US9149617B2 (en) * 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) * 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2012275417B9 (en) 2011-06-29 2017-08-31 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
AU2012275112B2 (en) 2011-06-29 2017-07-06 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20150064241A1 (en) * 2013-09-05 2015-03-05 Google Inc. Delivery of Functionalized Particles
JP7202070B2 (en) * 2015-05-01 2023-01-11 ラニ セラピューティクス, エルエルシー Pharmaceutical compositions and methods for fabrication of solid masses containing polypeptides and/or proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031770A2 (en) * 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2009063222A2 (en) * 2007-11-15 2009-05-22 Ucl Business Plc Solid compositions
US20120027775A1 (en) * 2010-08-02 2012-02-02 Advanced Technologies And Regenerative Medicine, Llc Absorbable peg-based hydrogels
WO2014066468A1 (en) * 2012-10-25 2014-05-01 Medimmune, Llc Stable, low viscosity antibody formulation
WO2015176031A2 (en) * 2014-05-15 2015-11-19 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LONNBERG ET AL: "Targeting of interleukin-17 in the treatment of psoriasis", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 1 September 2014 (2014-09-01), pages 251, XP055328086, DOI: 10.2147/CCID.S67534 *

Also Published As

Publication number Publication date
CA2984422C (en) 2023-10-17
JP2021042239A (en) 2021-03-18
CA2984422A1 (en) 2016-11-17
EP3294273A1 (en) 2018-03-21
WO2016183040A1 (en) 2016-11-17
AU2021269453A1 (en) 2021-12-16
CN107835682A (en) 2018-03-23
AU2016261599B2 (en) 2021-08-26
JP2018520995A (en) 2018-08-02
JP7185401B2 (en) 2022-12-07
AU2016261599A1 (en) 2017-11-23
JP7232805B2 (en) 2023-03-03

Similar Documents

Publication Publication Date Title
EP3706720A4 (en) Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
EP3316872A4 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3347050A4 (en) Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP2726091A4 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3962516A4 (en) Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
EP4003458A4 (en) Unilateral-driven drug infusion device
EP3294273A4 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP4149587A4 (en) Unidirectional-driven drug infusion device
EP3615113A4 (en) Medicinal inhaler drive mechanism
EP3302265A4 (en) Drug delivery capsule
EP3905999A4 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3445416A4 (en) Enteral drug delivery system
EP3260148A4 (en) Liquid drug administration device
IL279127A (en) Delivery devices for administering drugs
EP3263155A4 (en) Drug solution administering device
EP3597235A4 (en) Medicinal liquid administering device
EP3900727A4 (en) Immunity mechanism and therapeutic drug for gastrointestinal diseases
EP3846885B8 (en) Medicament delivery device
EP3925643A4 (en) Liquid medicine administration apparatus
EP3801703A4 (en) Tissue integrated drug delivery system
EP3925645A4 (en) Liquid medicine administration apparatus
EP3351286A4 (en) Device for administering drug solution
EP3773362A4 (en) Medical device delivery
EP3258990A4 (en) Micro infusion device for drug delivery
EP3661576A4 (en) Medical nebulizer for fast drug delivery

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181029

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 13/00 20060101ALI20181023BHEP

Ipc: A61K 9/20 20060101AFI20181023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RANI THERAPEUTICS, LLC

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524